Artificial Intelligence in Cerebrovascular Disease Management: A Comprehensive Review of Risk Prediction, Diagnosis, Therapeutic Optimization, and Clinical Translation

作者：Hengsheng Zhang, Wenhui Ma, Xingshun Zhou, Zinlin Zhao, Ruohan Zhang, Hong Bai, Cong Huang, Yujun Wang · 发表于：Vascular Health and Risk Management · 年份：2025 · DOI：10.2147/vhrm.s555592 · 被引用次数：5 · 研究领域：Artificial Intelligence in Healthcare and Education、Acute Ischemic Stroke Management、Intracerebral and Subarachnoid Hemorrhage Research

Cerebrovascular diseases (CVDs) impose a heavy global health burden, necessitating efficient management strategies. Artificial intelligence (AI) has become a key transformative tool across the CVD care continuum, and this review systematically synthesizes AI's latest advancements, limitations, and clinical translation pathways in CVD management, adhering to PRISMA-ScR guidelines. A literature search was performed in four core databases (PubMed, Web of Science, EMBASE, IEEE Xplore) for studies published between 2018-2023. After strict screening (inclusion: original research/clinical trials with clear indicators; exclusion: unvalidated studies/conference abstracts), 128 high-quality studies were included, with quality assessed via NOS and QUADAS-2. Key AI applications in CVD management include: (1) Risk prediction: Multimodal models (radiomics-CFD, EHR-imaging) achieve AUC >0.9, but performance declines in elderly patients (>75 years, ΔAUC=0.08-0.12); (2) Diagnosis: Systems like Viz LVO and DeepHemorrhage reduce LVO detection time to 6 minutes and hemorrhage segmentation Dice to 0.94, yet face false positives (3.5-5%) and workflow delays; (3) Therapeutic optimization: Intraoperative AI (eg, Siemens AI-Path) shortens microcatheter placement time by 61%, and pharmacogenomic models cut antiplatelet complications by 37%; (4) Long-term monitoring: Mobile platforms (eg, NeuroVision™) automate NIHSS scoring (ICC=0.93) but lose accuracy in home settings (ICC=0.85-0.88). Critical limita...